Skip to content

CareDx CDNA Additional Paid-In Capital

Additional Paid-In Capital at other companies

NeoGenomics logo
NeoGenomicsNEO
$1.28B+3.2%
Personalis, Inc. logo
Personalis, Inc.PSNL
$916.12M+18.5%
Veracyte logo
VeracyteVCYT
$1.7B+2.5%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Natera, Inc. logo
Natera, Inc.NTRA
Quest Diagnostics logo
Quest DiagnosticsDGX

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's additional paid-in capital?
CareDx (CDNA) reported additional paid-in capital of $1.05B in Q1 2026.
How has CareDx's additional paid-in capital changed year-over-year?
CareDx's additional paid-in capital increased by 2.9% year-over-year, from $1.02B to $1.05B.
What is the long-term trend for CareDx's additional paid-in capital?
Over 5 years (2020 to 2025), CareDx's additional paid-in capital has grown at a 10.5% compound annual growth rate (CAGR), from $632.25M to $1.04B.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.